HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA Regulation Of Homeopathics Does Not Pre-empt Damages Claims – Court

This article was originally published in The Tan Sheet

Executive Summary

A federal judge rejected an argument that FDA’s regulation of homeopathic drugs pre-empts a state consumer protection law.

You may also be interested in...

“Collateral Damage” From Pharma Regs Poses Threat To Homeopathics

The biggest threat to the homeopathic drug industry is “collateral damage” from regulation of pharmaceuticals, an industry leader says.

Science-Based Evaluation Advocates Want Tighter Homeopathic Oversight

Public health concerns should prompt FDA to tighten its regulation of homeopathic drugs, a citizen petition filed by the nonprofit Center for Inquiry says.

U.K. Homeopathic Online Claims Challenged In Wider Advertising Review

The U.K. advertising regulator asks homeopathic firms to remove online claims that their products can diagnose, treat or help diseases or health conditions.

Related Content





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts